-

Veradigm Strengthens Award-Winning Revenue Cycle Services Portfolio with Acquisition of Full-Service RCM Company

CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the acquisition of Koha Health, a full-service revenue cycle management (RCM) company. With this acquisition, Veradigm further adds to its depth of offerings and expertise as a leading provider of revenue cycle services in the ambulatory healthcare market.

“Today’s announcement represents an exciting opportunity for Veradigm to scale our revenue cycle services portfolio by leveraging additional capabilities and subject matter expertise to better serve the needs of the market,” said Tom Langan, President, and Chief Commercial Officer at Veradigm.

This acquisition brings additional Musculoskeletal Medicine (MSK) specialty subject matter expertise to the Veradigm Network along with an enhanced ability to deliver revenue cycle services to ambulatory healthcare provider practices and ambulatory surgical centers (ASCs) utilizing various electronic health record (EHR) systems. Veradigm is strengthening its end-to-end revenue cycle services portfolio to help bring added value to clients and unlock additional market opportunities.

“Key synergies exist, including expanded growth opportunities, enabling cost savings and improved service delivery all while continuing to focus on client satisfaction,” said Brian Hall, President, and Chief Executive Officer at Koha Health. “We are excited to join the Veradigm Network and leverage the additional tools and resources needed to help our clients achieve financial success and deliver a better patient experience.”

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

© 2023 Veradigm Inc. and/or its affiliates. All rights reserved.

Contacts

Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@veradigm.com

Veradigm Inc.

NASDAQ:MDRX

Release Versions
Hashtags

Contacts

Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@veradigm.com

More News From Veradigm Inc.

Veradigm Launches Smart Medicine Podcast to Explore the Evolution of Healthcare

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today launched the Smart Medicine Podcast, hosted by renowned podcaster and orthopedic surgeon, Dr. Scott Sigman. The show will provide insights and inspiration for clinicians along with other healthcare professionals, as well as payer and life science industry leaders striving to navigate the complexities of modern medicine through incremental insight. The podcast features exper...

Veradigm Recognized with KLAS 2025 Points of Light Award for Optimizing Value-Based Care

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, along with Metroplex Medical Centres and one of the largest healthcare payer organizations in the country, received a 2025 KLAS Points of Light Award. The case study titled, “Optimizing Value-Based Care by Delivering Insights at the Point of Care,” showcased how Veradigm and the payer integrated alerts into Metroplex Medical Centres’ electronic health record (EHR) to help improve...

Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today an advancement in the use of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide. By applying AI to electronic health record (EHR) deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights—such as side effects, dis...
Back to Newsroom